In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis (Q28582508)

31 January 2017

title

In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis (English)

1 reference

31 January 2017

1 reference

H. T. Silva

1

1 reference

31 January 2017

W. Cao

2

1 reference

31 January 2017

R. A. Shorthouse

3

1 reference

31 January 2017

M. Löffler

4

1 reference

31 January 2017

R. E. Morris

5

1 reference

31 January 2017

language of work or name

English

0 references

publication date

1 February 1997

1 reference

Transplantation Proceedings

31 January 2017

published in

1 reference

31 January 2017

volume

29

1 reference

31 January 2017

issue

1-2

1 reference

31 January 2017

page(s)

1292–1293

1 reference

Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection

31 January 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900523-4

7 January 2021

Immunopharmacological profile of HWA 486, a novel isoxazol derivative--II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone, or cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900523-4

7 January 2021

Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900523-4

7 January 2021

Regulation of B cell function by the immunosuppressive agent leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900523-4

7 January 2021

Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900523-4

7 January 2021

Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900523-4

7 January 2021

Inhibition of Protein Tyrosine Phosphorylation in T Cells by a Novel Immunosuppressive Agent, Leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900523-4

7 January 2021

Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900523-4

7 January 2021

Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900523-4

7 January 2021

The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900523-4

7 January 2021

Leflunomide interferes with pyrimidine nucleotide biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900523-4

7 January 2021

Catalytic enzyme histochemistry and biochemical analysis of dihydroorotate dehydrogenase/oxidase and succinate dehydrogenase in mammalian tissues, cells and mitochondria

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2896%2900523-4

7 January 2021

10.1016/S0041-1345(96)00523-4

Identifiers

DOI

0 references

1 reference